Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | HCK | P08631 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL995968 | 0.90 | KDR (0.41) | TGFBR1GRM2BRAFPIK3CDABL1 | |
| SCHEMBL995454 | 0.76 | NPC1 (0.50) | TGFBR1METAP2GRM1PIK3CDABL1 | |
| SCHEMBL15144395 | 0.75 | ALPG (0.44) | CYP17A1CYP11B1CYP11B2SRCNPC1 | |
| SCHEMBL997209 | 0.74 | NPSR1 (0.41) | NPC1SYKMAPK11MAPK14 | |
| SCHEMBL996389 | 0.73 | MAPK14 (0.44) | TGFBR1MAPK11MAPK14 | |
| SCHEMBL996478 | 0.73 | BRD4 (0.43) | NPC1S1PR1 | |
| SCHEMBL998539 | 0.72 | ALDH1A1 (0.47) | NPC1 | |
| SCHEMBL998117 | 0.71 | RAB9A (0.50) | NPC1MAPK14 | |
| SCHEMBL996183 | 0.70 | FPR2 (0.41) | — | |
| SCHEMBL998306 | 0.70 | ALDH1A1 (0.44) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233937-B2 | Method of stimulating insulin secretion and/or modulating INS-1 kinase with substituted pyrazinones and/or substituted tetrahydroquinoxalinones | MERCK PATENT GMBH (FR) | 2016-01-12 | — | — | US | claimed |
| US-20140329837-A1 | ARYLPYRAZINONES SUCH AS BUT NOT LIMITED TO 3-(4-CHLOROPHENYL-1-ETHYLPYRAZIN-2-(1H0)-ONE | MERCK PATENT GMBH (FR) | 2014-11-06 | — | — | US | claimed |
| US-8815859-B2 | Substituted pyrazin-2-ones and substituted 5,6,7,8-tetrahydroquinoxalin-2-ones and methods of use thereof | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | claimed |
| EP-2268624-B1 | ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2013-07-31 | — | — | EP | claimed |
| US-20110046159-A1 | Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GESELLSCHAFT (DE) | 2011-02-24 | — | — | US | claimed |
| EP-2268624-A1 | ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2011-01-05 | — | — | EP | claimed |
| WO-2009132739-A1 | ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-11-05 | — | — | WO | claimed |
| US-9233937-B2 | Method of stimulating insulin secretion and/or modulating INS-1 kinase with substituted pyrazinones and/or substituted tetrahydroquinoxalinones | MERCK PATENT GMBH (FR) | 2016-01-12 | — | — | US | disclosed |
| US-9233937-B2 | Method of stimulating insulin secretion and/or modulating INS-1 kinase with substituted pyrazinones and/or substituted tetrahydroquinoxalinones | MERCK PATENT GMBH (FR) | 2016-01-12 | — | — | US | disclosed |
| US-20140329837-A1 | ARYLPYRAZINONES SUCH AS BUT NOT LIMITED TO 3-(4-CHLOROPHENYL-1-ETHYLPYRAZIN-2-(1H0)-ONE | MERCK PATENT GMBH (FR) | 2014-11-06 | — | — | US | disclosed |
| US-20140329837-A1 | ARYLPYRAZINONES SUCH AS BUT NOT LIMITED TO 3-(4-CHLOROPHENYL-1-ETHYLPYRAZIN-2-(1H0)-ONE | MERCK PATENT GMBH (FR) | 2014-11-06 | — | — | US | disclosed |
| US-8815859-B2 | Substituted pyrazin-2-ones and substituted 5,6,7,8-tetrahydroquinoxalin-2-ones and methods of use thereof | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815859-B2 | Substituted pyrazin-2-ones and substituted 5,6,7,8-tetrahydroquinoxalin-2-ones and methods of use thereof | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| EP-2268624-B1 | ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2013-07-31 | — | — | EP | disclosed |
| EP-2268624-B1 | ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2013-07-31 | — | — | EP | disclosed |
| US-20110046159-A1 | Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GESELLSCHAFT (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046159-A1 | Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GESELLSCHAFT (DE) | 2011-02-24 | — | — | US | disclosed |
| EP-2268624-A1 | ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009132739-A1 | ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009132739-A1 | ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329837-A1 | ARYLPYRAZINONES SUCH AS BUT NOT LIMITED TO 3-(4-CHLOROPHENYL-1-ETHYLPYRAZIN-2-(1H0)-ONE | IAPP, GPR119, GLP1R | TGFBR1 1417/4885GRM2 3858/4885METAP2 1286/4885 |
| US-20110046159-A1 | Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | GLP1R, GPR119, IAPP | TGFBR1 517/4885GRM2 3626/4885METAP2 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.